JAMA Network Open:二代抗精神病药引发低钠血症的风险或存在差异
Hyponatremia risk may differ across second-generation antipsychotics
日本藤田医科大学研究团队在 JAMA Network Open 发表观察性研究,比较不同第二代抗精神病药与低钠血症风险的关联。
Antipsychotics are used to treat schizophrenia, along with bipolar disorder and major depressive disorder. However, these medications can be associated with hyponatremia, a serious reduction in blood sodium levels.
Although second-generation antipsychotics may carry a lower risk of hyponatremia than first-generation antipsychotics, it remains unclear whether this risk differs among individual second-generation medications.
Addressing this question, a research team led by associate professor Masakazu Hatano from the Department of Pharmacotherapeutics and Informatics at Fujita Health University School of Medicine in Japan, along with Dr. Takenao Koseki, Dr. Takeo Saito and Dr. Shigeki Yamada, all affiliated with the same institution, compared the risk of hyponatremia associated with individual second-generation antipsychotics.
The study was published in the journal JAMA Network Open.
"Hyponatremia is a safety concern associated with antipsychotic use, but comparative evidence among individual second-generation antipsychotics remains limited," says Hatano.
"We therefore adopted a two-stage approach. First, we used a spontaneous reporting system to generate hypotheses regarding hyponatremia risk among individual second-generation antipsychotics; second, we used a claims database to evaluate the associations obtained from the spontaneous reporting system."
Safety reports generate initial signals
The researchers first examined reports from the U.S. Food and Drug Administration Adverse Event Reporting System from the fourth quarter of 1997 to the third quarter of 2023, then evaluated the associations in a Japanese hospital-based claims database covering April 2008 to April 2024.
The U.S. safety reporting analysis included 17,805,418 reports, of which 458,745 involved second-generation antipsychotic monotherapy. Several antipsychotics showed lower reporting odds for hyponatremia than olanzapine, the reference antipsychotic.
Brexpiprazole and lurasidone showed the lowest reporting odds relative to olanzapine. However, these findings were hypothesis-generating because spontaneous reporting data do not provide denominator information and cannot measure actual incidence or absolute risk.
Aripiprazole shows lower adjusted risk
The researchers then evaluated the hypotheses using the Japanese hospital-based claims database. The final analysis included 55,394 patients who were prescribed antipsychotics and had no recent antipsychotic use or hyponatremia. They were followed for up to 180 days after treatment initiation. During follow-up, hyponatremia occurred in 366 patients (0.7%) in the cohort.
After accounting for differences in baseline characteristics and other factors influencing risk, aripiprazole was associated with a significantly lower risk of hyponatremia than olanzapine. Other antipsychotics did not show significant differences compared with olanzapine after adjustment.
"These findings suggest that the risk of hyponatremia may differ among individual second-generation antipsychotics," clarifies Hatano. "Aripiprazole was associated with a lower risk than olanzapine in our adjusted analysis, which may help inform antipsychotic selection for patients at higher risk of hyponatremia."
Observational findings warrant further study
However, the researchers emphasized that the study was observational, so residual confounding and differences in how hyponatremia was detected may have influenced the findings.
Overall, the study provides evidence that hyponatremia risk may not be identical across second-generation antipsychotics. By combining evidence from a pharmacovigilance database with claims data, the research provides complementary evidence for comparing drug safety while recognizing important limitations.
The findings will guide treatment decisions for patients at higher risk of hyponatremia. Further studies are needed to elucidate the associations between individual second-generation antipsychotics and hyponatremia.
Publication details
Masakazu Hatano et al, Comparative Risk of Hyponatremia Among Patients Treated With Second-Generation Antipsychotics, JAMA Network Open (2026). DOI: 10.1001/jamanetworkopen.2026.28796
Journal information: JAMA Network Open
Who's behind this story?
Swati Mestri
Swati Mestri holds a bachelor's degree in Electronics Engineering and has worked as a content editor since 2019. She has experience editing research documents across technology, health care, and materials science, and has a particular interest in technology and space. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Hyponatremia risk may differ across second-generation antipsychotics (2026, October 8) retrieved 8 October 2026 from https://medicalxpress.com/news/2026-10-hyponatremia-differ-generation-antipsychotics.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com